Otsuka Pharmaceutical to Acquire Avanir Pharmaceuticals

In late 2010, Avanir Pharmaceuticals obtained approval of the U.S. Food and Drug Administration (FDA) to market Nuedexta, the first drug for treating pseudobulbar effect, the uncontrollable bursts of laughing or crying that occurs in patients with ALS and several other neurological disorders (see Oct 2010 news story). Avanir has now been acquired by the US subsidiary of Otsuka Pharmaceuticals, Otsuka-America. The acquisition will not only give Otsuka marketing rights to Nuedexta, but also access to Avanir’s expertise in drug discovery development for neurological diseases.

In late 2010, Avanir Pharmaceuticals obtained approval of the U.S. Food and Drug Administration (FDA) to market Nuedexta, the first drug for treating pseudobulbar effect, the uncontrollable bursts of laughing or crying that occurs in patients with ALS and several other neurological disorders (see Oct 2010 news story). Avanir has now been acquired by the US subsidiary of Otsuka Pharmaceuticals, Otsuka-America. The acquisition will not only give Otsuka marketing rights to Nuedexta, but also access to Avanir’s expertise in drug discovery development for neurological diseases.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail